Company Overview of Biovest International Inc.
Biovest International, Inc., a biotechnology company, develops therapeutic cancer vaccines in the United States. It operates in two segments, Instrumentation and Vaccine. The company develops and commercializes BiovaxID, a personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. It is also involved in the development, commercialization, manufacture, and sale of instruments and disposables, including AutovaxID, an automated cell culture system that enables production of personalized cell-based treatments; HF Primer, a cell culture system for producing small quantities of the cell culture products from mammalian cell lines; and Multi-6, a cell culture system for produ...
300 South Hyde Park Avenue
Tampa, FL 33606
Founded in 1981
Key Executives for Biovest International Inc.
Chief Executive Officer and President
Executive Chairman and Member of Compensation Committee
Chief Financial Officer and Principal Accounting Officer
Director of Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2014.
Biovest International Inc. Key Developments
Biovest International Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 02:15 PM
Mar 12 14
Biovest International Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 02:15 PM. Venue: New York Academy of Sciences, New York, United States.
Biovest International Inc. Announces Executive Changes
Dec 5 13
Effective December 1, 2013, Biovest International Inc. hired Robert Farrell as Chief Financial Officer of the company. Prior to Mr. Farrell’s hiring, Brian Bottjer had been serving as acting Chief Financial Officer and Controller of the company. Mr. Bottjer will continue to serve as Controller of the company. Before Mr. Farrell’s appointment as Chief Financial Officer of the company, he served as Chief Financial Officer of Sanovas Inc., from 2012 to 2013. Mr. Farrell is a Member of the California Bar.
Shapiro Haber & Urmy LLP and Liggio Benrubi PA Files Class Action Lawsuit Against Accentia Biopharmaceuticals, Inc. and Officers and Directors of Accentia and Biovest International, Inc
Jul 30 13
Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (ABPI) and certain officers and directors of Accentia and Biovest International, Inc., a majority-owned subsidiary of Accentia, for violations of federal securities laws. The case has been filed in the United States District Court for the Middle District of Florida and is entitled Hill v. Accentia Biopharmaceuticals, et al., C.A. No. 13-cv-01945. The Complaint alleges that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Despite this information, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that the trial results were statistically significant and that Biovest was on track to obtain FDA approval. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act. The class action is brought on behalf of all persons and entities who purchased common stock of either Accentia or Biovest from July 26, 2008 through August 14, 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|